Approved: First Ever Human Trials Involving CRISPR Gene Editing

Cancer Cell. Image:
Cancer Cell. Image:
A team of Physicians at the University of Pennsylvania’s School of Medicine now has their project of modifying the immune cells of 18 different cancer patients with the CRISPR-Cas9 system approved by the National Institute of Health.

By Neil C. Bhavsar | Futurism

CRISPR is the gift that keeps on giving—when it’s not fighting blindness, tackling HIV, or even recording real-time immune responses, it is taking on the emperor of all maladies: cancer.

But what’s even more fascinating about this use of CRISPR is that the National Institute of Health’s (NIH) Recombinant DNA Research Advisory Committee (RAC) has approved the first-ever use of CRISPR in human cancer therapy, a monumental step in the history of the gene-editing technology.

While receiving funding from the Parker Immunotherapy Foundation, physicians at the University of Pennsylvania School of Medicine plan on working with the T-cells of 18 patients who have either melanoma, sarcoma, or myeloma by performing three distinct CRISPR edits:

read more